文献速递临床试验与 GCP

瑞格列克与亮丙瑞林在绝经前子宫肌瘤患者腹腔镜子宫肌瘤剔除术前预治疗中的有效性比较:一项随机对照研究方案(MyLacR研究)

The effectiveness of relugolix compared with leuprorelin for preoperative therapy before laparoscopic myomectomy in premenopausal women, diagnosed with uterine fibroids: protocol for a randomized controlled study (MyLacR study).
PubMed 文献 · Trials · 2024-05-24

该研究是一项多中心、随机、开放标签、平行组、非劣效性试验方案,计划纳入80例子宫肌瘤≥20岁绝经前女性,比较术前12周口服瑞格列克40 mg每日一次与亮丙瑞林皮下注射(1.88 mg或3.75 mg,每4周一次共三次)对腹腔镜子宫肌瘤剔除术中出血量的影响。主要结局为术中出血量(毫升),次要结局包括血红蛋白水平、肌瘤大小、其他手术结局及生活质量问卷。结论待试验完成后得出。

要点

  • 瑞格列克术前12周口服40 mg每日一次,对照亮丙瑞林皮下注射每4周一次共三次。
  • 主要结局为腹腔镜子宫肌瘤剔除术中出血量,采用非劣效性设计。
  • 计划纳入80例绝经前子宫肌瘤拟行腹腔镜子宫肌瘤剔除术的女性。

核心结论

  • 该方案旨在验证术前12周口服瑞格列克40 mg每日一次在减少腹腔镜子宫肌瘤剔除术中出血方面不劣于亮丙瑞林。

研究设计与样本

  • 多中心、随机、开放标签、平行组、非劣效性试验,计划纳入80例≥20岁绝经前子宫肌瘤拟行腹腔镜子宫肌瘤剔除术的女性。
  • 采用最小化法(预设因素:是否存在≥9 cm肌瘤及FIGO 1-5型肌瘤)随机化,按1:1分配。

主要发现

  • 瑞格列克为40 mg口服片,每日一次,术前12周至手术前一日服用。
  • 亮丙瑞林为1.88 mg或3.75 mg皮下注射,术前每4周一次共三次。
  • 主要结局术中出血量从体腔、手术海绵和收集袋中收集并以毫升测量。

关键数值与推荐

  • 主要结局指标为术中出血量(毫升)。
  • 次要结局指标为血红蛋白水平、肌瘤大小、其他手术结局及生活质量问卷(Kupperman Konenki Shogai Index和子宫肌瘤症状-生活质量量表)应答。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The oral gonadotropin-releasing hormone antagonist relugolix, which temporarily stops menstruation, is used to treat heavy menstrual bleeding, pelvic pressure, and low back pain in women with uterine fibroids. Treatment can also help women recover from low hemoglobin levels and possibly shrink the fibroids. However, evidence of preoperative use of relugolix before laparoscopic myomectomy is limited. Nevertheless, the treatment could reduce interoperative blood loss, decrease the risk of developing postoperative anemia, and shorten the operative time. Thus, we aim to test whether 12-week preoperative treatment with relugolix (40 mg orally, once daily) is similar to or not worse than leuprorelin (one injection every 4 weeks) to reduce intraoperative blood loss. METHODS: Efficacy and safety of preoperative administration of drugs will be studied in a multi-center, randomized, open-label, parallel-group, noninferiority trial enrolling premenopausal women ≥ 20 years of age, diagnosed with uterine fibroids and scheduled for laparoscopic myomectomy. Participants (n = 80) will be recruited in the clinical setting of participating institutions. The minimization method (predefined factors: presence or absence of fibroids ≥ 9 cm and the International Federation of Gynecology and Obstetrics [FIGO] type 1-5 fibroids) with randomization is used in a 1:1 allocation. Relugolix is a 40-mg oral tablet taken once a day before a meal, for 12 weeks, up to the day before surgery. Leuprorelin is a 1.88 mg, or 3.75 mg subcutaneous injection, given in three 4-week intervals during patient visits before the surgery. For the primary outcome measure of intraoperative bleeding, the blood flow is collected from the body cavity, surgical sponges, and collection bag and measured in milliliters. Secondary outcome measures are hemoglobin levels, myoma size, other surgical outcomes, and quality-of-life questionnaire responses (Kupperman Konenki Shogai Index and Uterine Fibroid Symptoms-Quality of Life). DISCUSSION: Real-world evidence will be collected in a clinical setting to use pre-treatment with an oral gonadotropin-releasing hormone antagonist to reduce intraoperative bleeding in women who undergo laparoscopic myomectomy. TRIAL REGISTRATION: jRCTs031210564 was registered on 19 January 2022 in the Japan Registry of Clinical Trials ( https://jrct.niph.go.jp ).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kitade M, Kumakiri J, Kobori H, et al. The effectiveness of relugolix compared with leuprorelin for preoperative therapy before laparoscopic myomectomy in premenopausal women, diagnosed with uterine fibroids: protocol for a randomized controlled study (MyLacR study). Trials. 2024. PMID: 38790029. doi:10.1186/s13063-024-08170-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。